Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Enzyme Inhibitors
  • Lung Neoplasms
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.

publication date

  • October 22, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1001/jama.290.16.2149

PubMed ID

  • 14570950

Additional Document Info

start page

  • 2149

end page

  • 58

volume

  • 290

number

  • 16